U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Officer the raperwork Reduction Act of 1995, no p	de 130113 are required to respond to a conection of find					
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A SUBMISSION UNDER 35 U.S.C. 371		Attorney Docket No.				
		U.S. Application No. (if known, see 37 CFR 1.5)				
International Application No.	International Filing Date	Priority Date Claimed				
Title of Invention						
First Named Inventor						
Applicant herewith submits to the United St	ates Designated/Elected Office (DO/EO/US)	the following items and other information.				
35 U.S.C. 371(f) will not be effective u	tional examination procedures (35 U.S.C. 371 nless the requirements under 35 U.S.C. 371(c Application and English translation thereof (if r	c)(1), (2), and (4) for payment of the basic				
	(35 U.S.C. 371(c)(2)) is attached hereto (not national Bureau or was filed in the United State					
3. An English language translation of the	International Application (35 U.S.C. 371(c)(2)))				
a. is attached hereto.						
b. has been previously submitted u	, , , ,					
4. An oath or declaration of the inventor(a. is attached.	s) (35 U.S.C. 3/1(c)(4))					
	ational phase under PCT Rule 4.17(iv).					
Items 5 to 8 below concern amendments ma	, , ,					
PCT Article 19 and 34 amendments	·					
5. Amendments to the claims under PCT (35 U.S.C. 371(c)(3)).	Article 19 are attached (not required if comm	unicated by the International Bureau)				
6. English translation of the PCT Article	19 amendment is attached (35 U.S.C. 371(c)(3	3)).				
7. English translation of annexes (Article attached (35 U.S.C. 371(c)(5)).	19 and/or 34 amendments only) of the Interna	ational Preliminary Examination Report is				
Cancellation of amendments made in the intern	national phase					
8a. Do not enter the amendment made in	the international phase under PCT Article 19.					
8b. Do not enter the amendment made in the international phase under PCT Article 34.						
NOTE: A proper amendment made in English instruction from applicant not to enter the amen		S. national phase application absent a clear				
The following items 9 to 17 concern a docur	nent(s) or information included.					
9. An Information Disclosure Statement	under 37 CFR 1.97 and 1.98.					
10. A preliminary amendment.						
11. An Application Data Sheet under 37 C	FR 1.76.					
12. A substitute specification. NOTE: A se	ubstitute specification cannot include claims. S	See 37 CFR 1.125(b).				
13. A power of attorney and/or change of	address letter.					
sequence listing in text format was ind	A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.3 and 37 CFR 1.821-1.825 (not required if sequence listing in text format was indicated on the PCT Request as part of the International Application and the sequence listing was published as part of the international application).					
15. Assignment papers (cover sheet and o	document(s)). Name of Assignee:					
16. 37 CFR 3.73(c) Statement (when then	e is an Assignee).					

A Federal agency may not conduct or sponsor, and a person is not required to respond to, nor shall a person be subject to a penalty for failure to comply with an information collection subject to the requirements of the Paperwork Reduction Act of 1995, unless the information collection has a valid OMB Control Number. The OMB Control Number for this information collection is 0651-0080. Public burden for this form is estimated to average 15 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the information collection. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden to the Office of the Chief Administrative Officer, United States Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450 or email InformationCollection@uspto.gov. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO-1390 (10-20)
Approved for use through 10/31/2022. OMB 0651-0021
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

U.S. APPLN. N	o. (if known – s	ee 37 CFR 1.5)	INTERNATIONAL	APPLICATION No. ATTORN		EY DOCKET No.		
17. Other items or information:								
The following	fees have be	en submitted.					CALCULATIONS	
18. Basic	national fee (3	37 CFR 1.492(a))			\$320	\$	
Examination fee (37 CFR 1.492(c)) If the written opinion prepared by ISA/US or the international preliminary examination report prepared by IPEA/US indicates all claims satisfy provisions of PCT Article 33(1)-(4)						\$		
Search fee (37 CFR 1.492(b)) If the written opinion prepared by ISA/US or the international preliminary examination report prepared by IPEA/US indicates all claims satisfy provisions of PCT Article 33(1)-(4)						\$		
					TOTAL OF	18, 19, and 20 =	\$	
Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence listing in compliance with 37 CFR 1.821(c) or (e) in an electronic medium or computer program listing in an electronic medium) (37 CFR 1.492(j)). Fee for each additional 50 sheets of paper or fraction thereof					\$			
Total Sheets	Extra Sheets	Number of each additional 50 or fraction			·			
- 100 =	- 100 = / 50 = x \$420				\$420			
Surcharge for furnishing any of the search fee, examination fee, or the oath or declaration after the date of commencement of the national stage (37 CFR 1.492(h))						\$		
CLAIMS	NU	MBER FILED	NUMBER EXTRA	RATE				
Total claim	ns	- 20 =		x \$100		\$		
Independent c	laims	- 3 =			x \$48 0	1	\$	
MULTIPLE DEPENDENT CLAIM(S) (if applicable) + \$860						\$		
Fee for submission of Sequence Listing text file of 300 MB to 800 MB (37 CFR 1.21(o)(1))					\$			
Fee for submission of Sequence Listing text file of more than 800 MB (37 CFR 1.21(o)(2))					\$			
Processing fee for furnishing the English translation later than 30 months from the earliest claimed priority date (37 CFR 1.492(i))					\$			
TOTAL OF ABOVE CALCULATIONS =					\$			
Applicant asserts small entity status. See 37 CFR 1.27. Fees above are reduced by ½.								
Applicant certifies micro entity status. See 37 CFR 1.29. Fees above are reduced by %. Applicant must attach form PTO/SB/15A or B or equivalent.								
TOTAL NATIONAL FEE =					\$			
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31)					\$			
TOTAL FEES ENCLOSED =					\$			

PTO-1390 (10-20)

Approved for use through 10/31/2022. OMB 0651-0021

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

а. 🗌	A check in the amount of \$	to 0	cover the above fees is end	losed.			
b	Please charge my Deposit Account No.		in the amount of \$_			to cover the above fees.	
	The Director is hereby authorized to charge additional fees which may be required, or credit any overpayment, to Deposit Account No as follows:						
i.	any required fee.						
ii.	any required fee except for excess claims f required under 37 CFR 1.492(f).	ees requ	ired under 37 CFR 1.492(d) and (e) an	d multiple de	ependent claim fee	
- Ш							
	ADVISORY: If filing by EFS-Web, do NOT attach the PTO-2038 form as a PDF along with your EFS-Web submission. Please be advised that this is not recommended and by doing so your credit card information may be displayed via PAIR . To protect your information, it is recommended to pay fees online by using the electronic payment method.						
NOTE: Where an appropriate time limit under 37 CFR 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the International Application to pending status.							
Stateme	nt under 37 CFR 1.55 or 1.78 for AIA (First Inv	entor to	File) Transition Applicat	ions			
This application (1) claims priority to or the benefit of an application filed before March 16, 2013, and (2) also contains, or contained at							
	y time, a claim to a claimed invention that has ar By providing this statement under 37 CFR 1.55		J	•		arch 16. 2013, will be	
examine	d under the first inventor to file provisions of	the AIA					
	A U.S. national stage application may not claim U.S. national stage application is the internation			on of which	it is the nati	onal phase. The filing	
Correspo	ondence Address						
The address associated with Customer Number: OR Correspondence address below							
Name							
Address							
City		State			Zip Code		
Country				Telephone	9		
Email							
Signature	3			Date			
Name (Print/Typ	pe)			Registrat (Attorney			

Privacy Act Statement

The **Privacy Act of 1974 (P.L. 93-579)** requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether disclosure of these records is required by the Freedom of Information Act.
- 2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
- 3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
- 4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
- 5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
- 6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- 8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspection or an issued patent.
- 9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.